APA (7th ed.) Citation

Hesselbarth, D., D’Orazio, M., Ciccarone, G., Gjermeni, D., Jülch, C., Wessinger, M., . . . Olivier, C. B. (2025). Fibrin clot strength is associated with increased risk of major adverse cardiac events after TAVR. Clinical research in cardiology, 114(11), . https://doi.org/10.1007/s00392-025-02749-7

Chicago Style (17th ed.) Citation

Hesselbarth, David, et al. "Fibrin Clot Strength Is Associated with Increased Risk of Major Adverse Cardiac Events After TAVR." Clinical Research in Cardiology 114, no. 11 (2025). https://doi.org/10.1007/s00392-025-02749-7.

MLA (9th ed.) Citation

Hesselbarth, David, et al. "Fibrin Clot Strength Is Associated with Increased Risk of Major Adverse Cardiac Events After TAVR." Clinical Research in Cardiology, vol. 114, no. 11, 2025, https://doi.org/10.1007/s00392-025-02749-7.